Latest Insider Transactions at Sigilon Therapeutics, Inc. (SGTX)
This section provides a real-time view of insider transactions for Sigilon Therapeutics, Inc. (SGTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Sigilon Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Sigilon Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 11
2023
|
Flagship Ventures Fund V General Partner LLC > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
797,720
-100.0%
|
$11,168,080
$14.92 P/Share
|
|
Aug 11
2023
|
Lilly & CO Eli > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,718,493
+99.99%
|
$24,058,902
$14.92 P/Share
|
|
Aug 11
2023
|
Josias Pontes CHIEF FINANCIAL OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,504
-100.0%
|
-
|
|
Aug 11
2023
|
Coelho Rogerio Vivaldi PRESIDENT AND CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
12,169
-100.0%
|
-
|
|
Aug 11
2023
|
Qing Sarah Yuan CTOO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,884
-100.0%
|
-
|
|
Aug 11
2023
|
Matthew Paul Kowalsky CHIEF OF STAFF AND CLO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,925
-100.0%
|
-
|
|
Aug 11
2023
|
John Cox |
SELL
Sale (or disposition) back to the issuer
|
Direct |
341
-100.0%
|
-
|
|
Jul 27
2023
|
Qing Sarah Yuan CTOO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,884
+50.0%
|
$54,796
$19.24 P/Share
|
|
Jul 21
2023
|
Coelho Rogerio Vivaldi PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,528
+31.6%
|
$105,032
$19.24 P/Share
|
|
Jul 21
2023
|
Josias Pontes CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,444
+30.74%
|
$27,436
$19.24 P/Share
|
|
Nov 04
2021
|
Coelho Rogerio Vivaldi PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+40.5%
|
-
|
|
Sep 30
2021
|
Josias Pontes CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
11,500
+46.3%
|
-
|
|
Jul 01
2021
|
Robert R Ruffolo |
SELL
Open market or private sale
|
Direct |
6,750
-100.0%
|
$67,500
$10.36 P/Share
|
|
Jul 01
2021
|
Robert R Ruffolo |
BUY
Exercise of conversion of derivative security
|
Direct |
6,750
+50.0%
|
$0
$0.57 P/Share
|
|
Jun 02
2021
|
Daniel Griffith Anderson |
SELL
Open market or private sale
|
Direct |
200,000
-9.0%
|
$2,000,000
$10.0 P/Share
|
|
Dec 08
2020
|
Coelho Rogerio Vivaldi PRESIDENT AND CEO |
BUY
Conversion of derivative security
|
Direct |
22,222
+50.0%
|
-
|
|
Dec 08
2020
|
John Cox |
BUY
Conversion of derivative security
|
Indirect |
4,444
+50.0%
|
-
|
|
Dec 08
2020
|
Flagship Ventures Fund V General Partner LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
10,370,369
+50.0%
|
-
|
|
Dec 08
2020
|
Lilly & CO Eli > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
300,000
+9.85%
|
$5,400,000
$18.0 P/Share
|
|
Dec 08
2020
|
Lilly & CO Eli > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,444,443
+50.0%
|
-
|